Trial-anchored psychedelic practice guidance

Manualized MDMA-assisted psychotherapy delivery

Deliver psychotherapy according to the study manual with fidelity across preparatory, experimental, integrative, and follow-up phases. Therapists must adhere to standardized session structure while supporting the subject’s therapeutic process.

General psychedelic-assisted practice skills

Prepare subjects for MDMA-assisted psychotherapy by building rapport, setting expectations, and establishing safety and rules. Preparatory work is intended to support readiness, consent, and therapeutic alliance before drug sessions.

General psychedelic-assisted practice skills

Help the subject process traumatic material during and after MDMA sessions and integrate insights into daily life. Integration work focuses on emotional stabilization, meaning-making, and transfer of adaptive states beyond the session.

Appropriate use of touch and physical proximity

Handle touch, proximity, assistance, and bodily contact with exceptional care because altered states can increase vulnerability and power asymmetry.

Professional boundaries and dual-role management

Maintain clear professional boundaries and prevent exploitation of the participant’s vulnerability, trust, or altered state.

Non-directive experiential support

Support the participant’s process without unnecessarily directing, controlling, or imposing meaning on the experience.

Professional qualification and role boundaries

Therapy teams must have appropriate education, experience, licensing, and defined supervision arrangements for delivering psychotherapy in the protocol.

Protocol-specific training and supervision

Therapists must complete sponsor-provided training and participate in ongoing clinical supervision to demonstrate competence in the manualized MDMA-assisted therapy method.

Manualized treatment fidelity

Therapists must deliver the treatment consistently across preparatory, Experimental, and Integrative Sessions while following visit-specific adherence criteria.

Continuous safety observation during dosing sessions

Monitor the participant closely during the MDMA or placebo session and respond promptly to physiological or psychological changes. Safety monitoring is frequent, structured, and clinically supervised.

Trauma-informed MDMA-assisted psychotherapy facilitation

Provide psychotherapy for chronic PTSD in a way that integrates an experimental MDMA session with preparatory and integrative therapy. The facilitator must be able to help participants work with traumatic material while maintaining safety, structure, and therapeutic intent.

Medical readiness and emergency response

Be prepared to manage rare but serious adverse events in an outpatient research setting. The therapist/facilitator role is embedded in a team that includes physician oversight and emergency capability.

Manualized MDMA-assisted psychotherapy delivery

Therapists must deliver psychotherapy according to the study manual with consistent structure across sessions. The manualized approach is central to treatment fidelity and study standardization.

Suicidality risk assessment and monitoring

Therapists must repeatedly assess suicidality and respond promptly to changes in risk. Suicide monitoring is built into screening, preparatory, dosing, integrative, and follow-up visits.

Physiological safety monitoring

Therapists must monitor vital signs and physical status during dosing sessions to detect MDMA-related physiological effects. They must know when to increase monitoring or involve medical support.

Preparatory session facilitation

Therapy teams must use preparatory sessions to build alliance, provide psychoeducation, and prepare participants for MDMA-assisted psychotherapy. These sessions establish safety, expectations, and readiness for treatment.

Integrative psychotherapy support

Therapists must conduct structured integrative sessions after each Experimental Session to help participants process and consolidate experiences. Integration includes reviewing session material, reducing distress, and translating insights into everyday life.

Clinical observation during MDMA administration

Therapists and site staff must actively monitor participant state during the 8-hour Experimental Sessions. They are expected to respond to behavioral, emotional, and medical changes in real time.

Establish ethical touch practices

Therapists should discuss and practice touch in a way that centers consent, boundaries, nonsexual intent, and immediate stoppability.

Monitor physical safety during sessions

Therapists are responsible for ongoing physical safety, including fall prevention, hydration, and close observation during movement and medication effects.

Practice nondirective, participant-led facilitation

A core competency is following rather than steering the participant’s process, intervening only in service of the unfolding inner-directed experience.

Professional qualification and scope

Therapy team members must have appropriate professional background, education, experience, and legal authorization to provide psychotherapy. Unlicensed members may participate only under direct supervision of a licensed team member.

Manualized MDMA-assisted psychotherapy knowledge

Therapists must understand and apply the Treatment Manual, study protocol, and current Investigator's Brochure. Competence is expected across preparatory, Experimental, and Integrative Sessions.

Non-directive therapeutic stance

The therapist uses a largely non-directive approach that supports the participant's spontaneous therapeutic process rather than directing the content or interpretation of the experience.

Therapeutic alliance and rapport

Build and maintain a strong, collaborative working relationship that provides psychological safety and supports social-skill practice. Establish trust while respecting the participant’s autonomy and preferred level of disclosure.

Preparation and informed expectation-setting

Prepare participants and support partners for the structure, risks, procedures, and emotional demands of experimental sessions. Ensure participants understand behavioral restrictions, monitoring, transportation, follow-up, and emergency procedures.

Nondirective and choice-based facilitation

Facilitate experimental sessions primarily through a nondirective, supportive approach that allows the participant to follow their experience while remaining emotionally and physically safe. Offer gentle guidance only when clinically indicated.

PTSD clinical assessment

Understands the diagnostic and severity framework for PTSD and related symptom domains used in the protocol. Can support accurate identification of eligible participants and interpret symptom changes over time.

Suicide and serious psychiatric risk assessment

Can monitor suicide risk throughout the study and respond appropriately to escalating risk. This includes using C-SSRS, clinical judgment, escalation pathways, and emergency procedures.

Physiologic monitoring, thermoregulation, hydration, and overdose response

Can monitor participants for acute medical complications related to MDMA, especially cardiovascular and neurologic concerns. Facilitators must recognize warning signs and escalate rapidly to medical staff.

Clinical monitoring during sessions

Continuously observe the subject for physiological and psychological changes during experimental sessions. Monitoring is intended to detect adverse reactions, distress, or instability early enough to intervene.

Suicide risk assessment and management

Assess suicidality repeatedly throughout the protocol and respond to elevated risk with appropriate clinical action. The C-SSRS is used to detect suicidal ideation and behavior before, during, and after sessions.

Serious adverse event reporting

Report serious adverse events promptly through required sponsor and regulatory channels. Rapid communication is a core safety responsibility of the investigator team.

Suicide risk assessment and response

Therapists must identify and respond to suicidal ideation and behavior using the C-SSRS and clinical judgment. The protocol provides explicit escalation steps for imminent risk and requires documentation and emergency intervention when necessary.

Manualized MDMA-assisted psychotherapy delivery

Therapists must deliver a largely non-directive, manualized psychotherapy model in a standardized way across preparatory, experimental, and integrative sessions. The protocol emphasizes consistent application of the Treatment Manual and visit-specific adherence criteria.

Safety monitoring during psychotherapy sessions

Therapy teams must continuously monitor participant safety during all contacts, including Experimental Sessions, phone follow-ups, and Integrative Sessions. They are responsible for recognizing distress, changes in mental status, and emergent risk.

Social anxiety disorder clinical knowledge

Understanding of social anxiety disorder, particularly generalized subtype moderate-to-severe presentations, including its impact on functioning and quality of life. Knowledge of relevant symptoms and treatment goals is required to appropriately support participants.

Safety and feasibility monitoring

Competence in monitoring feasibility and safety throughout the trial and therapy course. The protocol explicitly identifies safety outcomes as a key study aim alongside treatment effects.

Trial protocol adherence

Ability to work within a randomized, open-label delayed-treatment clinical trial structure. This includes following assignment procedures, session timing, and outcome-assessment requirements.

Clinical trial protocol literacy

The therapist/facilitator should understand the study protocol and how to apply it consistently during participant sessions. This includes awareness of study procedures and the role of the facilitator within the trial framework.

Data element and documentation awareness

The facilitator should be familiar with study documentation concepts relevant to registration and results reporting. This supports accurate handling of study-related information and records.

Regulatory and reporting compliance

The facilitator should follow the reporting and submission expectations associated with ClinicalTrials.gov records. Ethical conduct includes using the correct information pathways for study registration and results submission.

PTSD clinical assessment

Understands DSM-5 PTSD criteria, symptom severity thresholds, and trauma history assessment needed for enrollment and ongoing care. Uses standardized instruments to confirm diagnosis and monitor symptom change.

Non-directive psychedelic psychotherapy facilitation

Applies the manualized, non-directive MDMA-assisted psychotherapy model consistently across all sessions. Facilitates processing by inviting inquiry, offering support, and avoiding unnecessary direction.

Integrative psychotherapy

Helps participants process and integrate experiences from MDMA sessions into daily life. Supports emotional meaning-making, stabilization, and transfer of insights to everyday situations.

Structured experimental-session facilitation

Ability to facilitate long-duration psychotherapy sessions in a controlled research setting. The study used two 8-hour psychotherapy sessions, requiring sustained therapeutic presence and session management.

Clinical trial protocol adherence

Ability to work within a randomized, double-blind, crossover clinical trial design. Therapists/facilitators must support protocol fidelity and coordinated study procedures.

Support for vulnerable medical populations

Knowledge of working with patients experiencing life-threatening illness and associated psychological burdens. Therapists must appreciate the emotional and existential context of serious medical disease.

Suicidality risk assessment and monitoring

Continuously assess suicide risk before, during, and after treatment sessions. The protocol requires active monitoring using clinical interview, the C-SSRS, and judgment when risk emerges.

Adverse event surveillance

Observe and document adverse events across all phases of treatment, with special attention during dosing sessions and shortly afterward. Respond to medical or psychiatric complications promptly.

MDMA-assisted therapy delivery

Provide MDMA in a therapeutic setting across preparatory, dosing, and integration phases. Maintain the protocol structure while using the drug as a catalyst for psychotherapy rather than a standalone intervention.

MDMA-assisted therapy delivery

Deliver MDMA-assisted therapy in a structured protocol with preparation, dosing, and integration phases. The therapist must support the participant through the full treatment course while maintaining fidelity to the manualized approach.

Suicidality monitoring

Continuously monitor suicide risk throughout treatment, including emergence of active suicidal ideation. This is a core safety competency in this population.

Ethical conduct under GCP and Helsinki principles

Practice in accordance with formal research and clinical ethics standards. This includes informed consent, participant welfare, and adherence to Good Clinical Practice and the Declaration of Helsinki.

Manualized MDMA-assisted therapy delivery

The therapist/facilitator must be able to deliver the intervention according to a manualized protocol. This includes integrating MDMA or placebo sessions with structured preparatory and integration therapy.

Safety monitoring and adverse event awareness

Therapists/facilitators must actively monitor participant safety throughout treatment. The study tracked adverse events and suicidality across the trial.

Blinded trial conduct

Therapists/facilitators must operate within a double-blind placebo-controlled study environment. This requires maintaining protocol integrity and avoiding inadvertent unblinding.

Acute psychological response and emergency management during dosing

Closely monitors physiological and psychological status throughout the experimental session and follow-up contacts. Adjusts the frequency of assessment based on clinical judgment and participant needs.

Suicide and serious psychiatric risk assessment

Assesses suicidality repeatedly and responds to changes in risk during all phases of the study. Ensures escalation and support when self-harm risk emerges.

Acute psychological response and emergency management during dosing

Prepared to manage medical and psychiatric emergencies that may occur during the MDMA session or overnight stay. Coordinates on-site emergency resources and transfer to higher care when necessary.

Regulatory and protocol compliance

Therapists/facilitators must work within an FDA- and IRB-approved research protocol and comply with controlled-substance licensing requirements governing MDMA-assisted psychotherapy.

Informed consent administration

Therapists/facilitators must ensure participants are properly informed using approved consent materials before participation in MDMA-assisted psychotherapy research.

MDMA-assisted psychotherapy delivery

Therapists/facilitators must be able to deliver psychotherapy in conjunction with MDMA according to the study treatment manual for PTSD.

Acute physiological monitoring

Facilitators must be competent in frequent scheduled monitoring of vital signs and distress during MDMA sessions, with clear escalation thresholds.

Emergency medical readiness

The protocol requires immediate capability to recognize and manage acute medical emergencies, including collaboration with emergency-trained staff and use of resuscitation equipment.

Management of psychological distress and destabilization

Facilitators must be able to prevent, recognize, and manage panic, severe anxiety, agitation, suicidality, or post-session destabilization with escalating levels of support.

General psychedelic-assisted practice skills

Clinical staff must monitor vital signs throughout the drug session and recognize abnormal trends that may require intervention or discontinuation. Monitoring is required every 30 minutes during drug visits.

Emergency recognition, escalation, and disposition planning

Clinicians and coordinators must be prepared to implement protocol-specific emergency responses, call 911 when indicated, and initiate BLS/ACLS when needed. The framework includes explicit responses for myocardial infarction, desaturation, hypertension, arrhythmia, cardiac arrest, allergic reaction, nausea, and other emergencies.

Informed consent, decisional capacity, autonomy, and withdrawal rights

Trained research staff must clearly explain the study, answer participant questions, and obtain written informed consent before enrollment. Consent includes explanation of randomization, study procedures, and optional saliva sampling with no effect on eligibility if declined.

Deliver manualized MDMA-assisted psychotherapy

Therapists/facilitators must competently deliver the protocolized MDMA-assisted psychotherapy model across preparatory, experimental, and integrative phases while maintaining consistency with the treatment manual. The role requires non-directive yet active therapeutic engagement that supports spontaneous participant experience without imposing direction.

Suicide risk assessment and management

Therapists must competently assess suicidal ideation and behavior throughout the protocol and implement specified escalation pathways for elevated or imminent risk. This includes use of the C-SSRS, clinical follow-up, emergency intervention, and documentation/reporting.

Training, competence development, and adherence monitoring

Therapists/facilitators must complete specialized training and demonstrate competence in the protocol and treatment method. Ongoing adherence monitoring through recorded sessions and blinded ratings is part of the required competency framework.

Monitoring and response to acute psychological distress

Therapy pairs must continuously monitor for anxiety, panic, agitation, suicidality, psychosis, or destabilization and respond promptly. The protocol specifies prolonged observation, supportive techniques, medication options, escalation, and emergency transfer pathways.

Suicide risk assessment and crisis intervention

A core facilitator competency is evaluating suicidal ideation and behavior using the C-SSRS and responding according to risk level. The protocol requires coordinated action with investigators, site physicians, personal therapists, and emergency services when necessary.

Medical safety monitoring during Experimental Sessions

Therapy teams must monitor vital signs and detect medical complications during MDMA administration. They need to recognize symptoms that may indicate cardiovascular, cerebrovascular, or other medical emergencies and involve the site physician promptly.

Crisis escalation and hospitalization decision-making

Therapists must be able to recognize acute psychiatric risk and escalate care appropriately. If a participant is severely dysregulated or presents imminent risk, hospitalization is required until stabilization.

Management of dual relationships and undue influence

Therapists must protect voluntariness when potential participants are also their patients. Independent evaluation should be used to reduce pressure or perceived coercion in recruitment and consent.

Overnight post-session care planning

Therapists/facilitators must ensure participants are safely monitored after experimental sessions rather than being discharged immediately. This includes arranging secure overnight accommodation and next-day transport after follow-up care.

PTSD and psychotherapy foundation

Demonstrate standard training in PTSD psychotherapy and understand trauma symptoms, comorbidity, trauma processing, and therapeutic exposure. Understand the importance of emotional engagement while avoiding dissociation, overwhelming affect, and retraumatization.

MDMA-assisted therapy knowledge

Understand the psychological, physiological, and interpersonal effects of MDMA and how they may interact with psychotherapy. Recognize that MDMA is a therapeutic tool or catalyst, not the therapy itself.

Clinical assessment and eligibility

Conduct or appropriately coordinate structured diagnostic, psychiatric, medical, and risk assessments before treatment. Determine whether participation is clinically and medically appropriate under the protocol.

Ethical use of touch and focused bodywork

Therapists must use nurturing touch or focused bodywork only with careful preparation, clear consent, ongoing communication, appropriate boundaries, and sensitivity to vulnerability.

Professional qualification and protocol training

Therapists must have appropriate clinical education, therapy experience, and specialized training in the MDMA-assisted psychotherapy method and approved research procedures.

Trauma and MDMA-assisted therapy knowledge

Therapists require a thorough understanding of PTSD, trauma processing, MDMA effects, non-ordinary states of consciousness, and the nonlinear course of therapeutic change.

Practice within credentialed scope and trial regulations

Therapists must already be trained, competent, and credentialed psychotherapists and are responsible for practicing within their scope and applicable regulatory requirements. The manual is designed for use within approved clinical trials and requires protocol adherence.

Prioritize participant wellbeing over research aims

Participant safety and wellbeing must take precedence over scientific objectives at all times. Therapists must communicate and operationalize this priority throughout screening, treatment, and follow-up.

Client-centered and non-directive stance

Therapists need a client-centered orientation and the ability to support the participant's process without imposing a predetermined agenda. The core skill is balancing permission and receptivity with timely, sensitive intervention when needed.

Follow-up and integration

Support post-session processing and therapeutic integration after MDMA-assisted sessions.

Screening and contraindication assessment

Identify prerequisites and contraindications before participation in MDMA-assisted psychotherapy.

Therapeutic alliance

Establish and maintain a therapeutic alliance during preparation, treatment, and follow-up.

Safety-first clinical judgment

Therapists must prioritize participant safety and wellbeing over scientific goals and continuously judge when to intervene, witness, or escalate care. They must monitor both psychological and physical stability throughout preparation, dosing, overnight support, and integration.

Empathic presence and listening

Therapists must listen with nonjudgmental, emotionally attuned presence and convey validation, reassurance, and curiosity. They should be able to stay relaxed yet engaged, including noticing nonverbal cues and responding without prying.

Non-directive facilitation

Therapists must facilitate rather than control the participant's process, using invitations and timing interventions carefully. They should preserve the participant-led unfolding of experience while knowing when gentle direction or safety-based assertiveness is needed.

Participant screening and contraindication review

Therapists must screen for psychiatric and medical exclusion criteria and determine whether MDMA-assisted psychotherapy is appropriate. This includes evaluating suicide risk, psychosis, bipolar I, substance use, pregnancy, and medical instability.

Informed consent and study-rule adherence

Therapists must clearly explain the experimental nature of the treatment, the session structure, safety procedures, and participant obligations. Ongoing participation remains voluntary and can be withdrawn at any time.

Therapeutic alliance building

A safe and positive therapeutic alliance is an absolute prerequisite for treatment. Therapists must establish trust, rapport, and collaboration during preparation and maintain this alliance throughout the process.

Informed consent responsibility

Facilitators are responsible for ensuring that participants have provided informed consent before receiving MDMA-assisted therapy. This reflects an ethical and regulatory duty central to work with investigational treatments.

MDMA-assisted therapy protocol adherence

Therapists must deliver MDMA-assisted psychotherapy according to the structured clinical trial treatment manual and adherence model rather than improvising outside protocol. This includes applying the manualized method consistently in approved research settings.

Clinical trial participant eligibility boundaries

Therapists must practice within the population and setting defined by the manual, limiting use to approved clinical trial subjects with PTSD. This boundary helps protect participants and preserves research integrity.

Maintain ethical boundaries and consent around touch

Therapists must maintain strict sexual and relational boundaries while using touch only within clear consent-based therapeutic limits. Ethical management of vulnerability is central to safe care in an altered state context.

Respond to acute anxiety and panic during sessions

Therapists must competently manage acute fear, panic, or distress arising during MDMA sessions using reassurance, grounding, breathing cues, touch when consented, and containment. They should escalate interventions stepwise and use rescue medication only if necessary.

Orient patient to treatment process

Therapists must clearly educate and orient patients to the scope, phases, goals, expectations, and experiential nature of MDMA-assisted psychotherapy. This includes explaining that MDMA is an adjunctive ally rather than the therapy itself.

MDMA-assisted psychotherapy method training

Therapists must complete specific training in the MDMA-assisted psychotherapy method, study protocol, and Investigator Brochure before serving as investigators. Competence includes understanding the standardized method while applying sound clinical judgment.

Client-centered, non-directive stance

A core competency is maintaining a largely non-directive, client-centered orientation that follows the participant’s unfolding process rather than imposing a predetermined agenda. Therapists must balance allowing spontaneous process with timely supportive guidance when indicated.

Empathic presence and active listening

Therapists are expected to provide consistent empathic presence, nonjudgmental attunement, and deep listening throughout the process. This includes validating feelings, listening for deeper meaning, and creating psychological permission for openness.

Safety attunement

Maintain physical, emotional, and relational safety as the primary guiding principle throughout IMAP. Therapists continuously monitor risk, reinforce boundaries, and intervene more directly when safety is compromised.

Boundary management

Maintain strict therapeutic boundaries in a context of heightened emotional openness and vulnerability. Clear boundaries reduce risk of harm, dependency, and misconduct.

Safety monitoring and medical escalation

Monitor physiological changes and recognize when medical evaluation is required. Therapists must know warning signs and follow protocol for escalation to a physician or emergency response.